Brought to you by 
Agios brings in $78mm through Series C; expands research scope
07 Dec 2011
Executive Summary
Oncology biotech Agios Pharmaceuticals Inc. raised $78mm through its Series C round. Development partner Celgene participated, along with returning buyers Arch Venture Partners, Flagship Ventures, Third Rock Ventures, and three undisclosed large public investment funds. Celgene's COO Perry Karsen has joined the company's board. Agios will use the proceeds to continue developing its pipeline of cancer metabolism therapies, and will also expand its research into the field of genetic disorders, specifically inborn errors of metabolism.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Agios brings in $78mm through Series C; expands research scope
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice